Slaughter and May advised Alliance Pharma plc (“Alliance”) on its recommended acquisition by Aegros Bidco Limited (“Bidco”). The takeover offer, announced on 10 January 2025, was effected by means of a court-sanctioned scheme of arrangement.
The scheme of arrangement was sanctioned by the High Court on 12 May 2025 and became effective in accordance with its terms on 14 May 2025.
The cash offer valued Alliance at approximately £362 million and, on the basis of the closing price per Alliance share on 9 January 2025 prior to the start of the offer period, represented a premium of approximately 46%. As an alternative to the cash offer, shareholders also had the option to exchange some or all of their shares for rollover shares to be issued by an indirect holding company of Bidco.
Alliance is an international consumer healthcare company targeting the markets of France, USA, Germany, China and the UK with a bespoke operating model within each market to increase the reach of their brand. Headquartered in the UK, Alliance operates from eight offices around the world and has an extensive network of distributors to serve customers in more than 100 countries.
Julian Quak / Trainee Solicitor, Carys Miller / Trainee Solicitor